Recent Updates
Recently added Catalysts
EXOZ Positive Sentiment

eXoZymes Reports Third Quarter 2026 Results and Provides Business Update at 5PM ET Today

Key Takeaway: eXoZymes Inc. reported its third quarter results for 2026 and announced an investor webinar for updates. CEO Michael Heltzen highlighted progress in commercial manufacturing and the expansion of their product pipeline. The company aims to transform its technology into a scalable production engine for valuable nutraceuticals and medicines.

Market Sentiment Analysis

POSITIVE FACTORS

  • eXoZymes is advancing its lead product toward commercial manufacturing.
  • The company is expanding its pipeline of high-value molecules.
  • CEO expresses confidence in the technology's scalability.

Full Press Release Details

The first and only All-in-one subscription platform offering all of your PR Distribution and Media Outreach Tools in one single solution. Monthly & Annual Subscriptions.
Find & create journalist lists with the most up to date database in the industry.
Personalize and customize your pitch for maximum engagement.
Discover your brand, industry, and competitor mentions.
Now you can track every mention, every conversation, and every shift in sentiment — all from the platform you're already using.
Turn your PR data into actionable intelligence with comprehensive reporting and analytics on every campaign.
Catch issues before our editors do. ACCESS Verified gives you a real-time first pass on your press release so you can submit with confidence — every time.
The first and only All-in-one subscription platform that offers you the ability to manage all of your IR communications needs from a single source. Explore our IR subscriptions
Explore how you can upgrade your IR Site today.
Ensure your IR Site is accessible for your entire audience.
Experience seamless calls with our dedicated team of domestic operators.
Easily send your releases out with quick turnarounds and no extra fees.
Host your day knowing you've got the most experienced webcast team in the industry.
Provide a secure and confidential reporting channel to protect your organization and employees.
Streamline your PR & IR needs with one platform.
Easily schedule and manage your investor meetings with our comprehensive and easy to use software.
Our PR and IR tools are designed to meet all necessary regulatory requirements, giving you the confidence to communicate effectively and compliantly. Streamline your communications needs today with our one-stop shop offering.
Whether a startup or established brand, we deliver the support, targeted distribution, media outreach, and flexible pricing & payment options needed to amplify your story with confidence.
We simplify the process of delivering success for both you and your clients. We understand the importance of getting it right, equipping you with seamless billing, flexible plans and payment structures, and clear reporting and analytics to ensure every campaign runs smoothly and achieves measurable results.
We understand the need to manage high volume of press release distribution efficiently. That's why we offer a dedicated API designed specifically for our legal customers, delivering a streamlined, simple process that ensures value and ease at every step.
We understand the importance of cost efficiency for high-volume partners, which is why we offer bulk discounts tailored to meet your needs while maximizing value.
Designed for brands that need help consistently fueling their content strategy and calendar with optimized press releases, blogs, and more…
Tailored for brands with a solid content strategy seeking support for effectively reaching and engaging the media.
Made for brands that need more comprehensive support building and managing their content strategy, media outreach and engagement plan.
Personalized support to optimize your platform, including tailored journalist list creation, pitch guidance, and monitoring setup.
Continual support and management including ongoing list creation, pitch creation and modifications, monitoring adjustments, and additional reporting and analytics review.
Press Release creation and optimization for SEO and audience engagement
Back to the Newsroom eXoZymes Reports Third Quarter 2026 Results and Provides Business Update at 5PM ET Today Thursday, 19 November 2026 04:25 PM
LOS ANGELES, CA / ACCESS Newswire / November 19, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - will host an investor webinar at 5:00 PM Eastern Time to discuss results for the third quarter ended September 30, 2026, and provide an update on recent business developments.
Michael Heltzen, CEO of eXoZymes, states, " We're entering an exciting new phase for eXoZymes as we advance our lead product toward commercial manufacturing while expanding our pipeline of high-value molecules. Our progress with Curia and the advancement of additional product candidates demonstrate how we intend to turn our technology into a repeatable engine for commercial opportunities. We believe our ability to move rapidly from discovery toward scalable production is what sets our platform apart. "
Investors and interested parties can access the live webinar through eXoZymes' investor relations website at: https://video.exozymes.com/exoz-investor-update-3q26-nov-19
Michael Heltzen, CEO of eXoZymes, will lead the call and be joined by select members of the management team to review recent developments and ongoing initiatives. A recording and transcript of the conference call will also be made publicly available following the event.
About eXoZymes Founded in 2019, eXoZymes is pioneering a cell-free biomanufacturing platform that uses AI-enhanced enzymes - called exozymes - to make valuable natural products and new analogs outside living cells. The company's platform is designed to replace inefficient extraction and petrochemical processes with a scalable way to produce high-value molecules for nutraceutical and pharmaceutical markets.
eXoZymes is building a portfolio of biosolutions across NCT - now Tyferyn for human use - cannabinoid analogs, santalene, and other high-value natural product molecules, with potential commercialization paths that include partnerships, licensing and joint ventures. Learn more at exozymes.com
eXoZymes Safe Harbor This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely," "potential," or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of eXoZymes' quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.

Frequently Asked Questions

What did eXoZymes report for Q3 2026?

eXoZymes reported its third quarter results and business updates.

When is the investor webinar for eXoZymes?

The investor webinar is scheduled for 5:00 PM ET today.

Who is leading the investor call?

CEO Michael Heltzen will lead the investor call.

What is the focus of eXoZymes' business?

eXoZymes focuses on AI-enhanced enzymes for nutraceuticals and medicines.

Last updated: Nov 19, 2026